Home > G. Tumoral pathology > myxoid liposarcoma

myxoid liposarcoma

Thursday 1 November 2007

Myxoid liposarcoma displays variably aggressive behavior and responds poorly to available systemic therapies.

Immunochemistry

- detection of TLS/EWS or TLS/DDIT3 (FUS/CHOP) chimeric oncoprotein by monoclonal antibody(#16538055#)

Cytogenetics

- t(12;16)(q13;p11) creating a TLS/DDIT3 fusion gene (FUS-CHOP fusion gene)

Molecular biology

- TLS/DDIT3 fusion gene (FUS/CHOP fusion gene) by t(12;16)(q13;p11)
- EWS/CHOP fusion gene (#12169678#, #16884691#)

- detection of TLS/EWS or TLS/DDIT3 (FUS/CHOP) chimeric oncoprotein by monoclonal antibody (#16538055#)

Expression studies

- Expression levels of the ret proto-oncogene (RET), insulin-like growth factor 1 receptor (IGFR1), and insulin-like growth factor 2 (IFG2) correlate with poor metastasis-free survival, supporting a role for ERK/MAPK and PI3K/AKT pathways in clinically aggressive myxoid liposarcomas. (#19368956#)

See also

- adipocytic tumors

  • liposarcomas
    • myxoid/round cell liposarcoma

Open access references

- Detection of myxoid liposarcoma-associated FUS-DDIT3 rearrangement variants including a newly identified breakpoint using an optimized RT-PCR assay. Powers MP, Wang WL, Hernandez VS, Patel KS, Lev DC, Lazar AJ, L√≥pez-Terrada DH. Mod Pathol. 2010 Oct;23(10):1307-15. PMID: #20581806# [Free]

References

- Validation of immature adipogenic status and identification of prognostic biomarkers in myxoid liposarcoma using tissue microarrays. Cheng H, Dodge J, Mehl E, Liu S, Poulin N, van de Rijn M, Nielsen TO. Hum Pathol. 2009 Apr 13. PMID: #19368956#

- Matsui Y, Ueda T, Kubo T, Hasegawa T, Tomita Y, Okamoto M, Myoui A, Kakunaga S, Yasui N, Yoshikawa H. A novel type of EWS-CHOP fusion gene in myxoid liposarcoma. Biochem Biophys Res Commun. 2006 Sep 22;348(2):437-40. PMID: #16884691#

- Oikawa K, Ishida T, Imamura T, Yoshida K, Takanashi M, Hattori H, Ishikawa A, Fujita K, Yamamoto K, Matsubayashi J, Kuroda M, Mukai K. Generation of the novel monoclonal antibody against TLS/EWS-CHOP chimeric oncoproteins that is applicable to one of the most sensitive assays for myxoid and round cell liposarcomas. Am J Surg Pathol. 2006 Mar;30(3):351-6. PMID: #16538055#

- Crozat A, Aman P, Mandahl N, Ron D. Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma. Nature. 1993 Jun 17;363(6430):640-4. PMID: #8510758#

- Mrozek, K.; Karakousis, C. P.; Bloomfield, C. D. : Chromosome 12 breakpoints are cytogenetically different in benign and malignant lipogenic tumors: localization of breakpoints in lipoma to 12q15 and in myxoid liposarcoma to 12q13.3. Cancer Res. 53: 1670-1675, 1993. PubMed ID : #8453640#

- Rabbitts, T. H.; Forster, A.; Larson, R.; Nathan, P. : Fusion of the dominant negative transcription regulator CHOP with a novel gene FUS by translocation t(12;16) in malignant liposarcoma. Nature Genet. 4: 175-180, 1993. PubMed ID : #7503811#

- Aman, P.; Ron, D.; Mandahl, N.; Fioretos, T.; Heim, S.; Arheden, K.; Willen, H.; Rydholm, A.; Mitelman, F. : Rearrangement of the transcription factor gene CHOP in myxoid liposarcomas with t(12;16)(q13;p11). Genes Chromosomes Cancer 5: 278-285, 1992. PubMed ID : #1283316#

Portfolio

  • Myxoid liposarcoma
  • Myxoid liposarcoma
  • Myxoid liposarcoma
  • Calretinin immunostaining
  • CD34 immunostaining
  • CD34 immunostaining
  • CD34 immunostaining
  • Oil-red-O
  • Oil-red-O